Possible new ALGS shares
ALGSDilution
Known so far: no new shares from the prospectus covers read · shelf room about $6.6M · not yet read: warrants, converts, options, ATM.
Shelf room
- Room today about $6.6M
- One third of float $6.6M ($19.9M float, Jun 30, 2025)
- Sold off it, 12 months nothing
How this is worked out
Shelf room about $6.6M on the S-3 of Mar 27, 2025: the baby-shelf rule (public float under $75M) caps sales at one third of the $19.9M public float stated as of Jun 30, 2025, $6.6M, nothing sold off it in the last 12 months. Sources: S-3 Mar 27, 2025, effective Apr 3, 2025 · public float, as of Jun 30, 2025.
What could become new Aligos Therapeutics (ALGS) shares, from its 10-Q, 10-K, S-3 or 424B filings.
We have not read ALGS's share count or any source of new shares yet. Not read yet: warrants, convertible notes, options and RSUs and an ATM program. Read them on EDGAR: S-3 shelf filings.
Shares outstanding
6.2M
Sep 2024 to Mar 2026: from 133K to 6.2M. Adjusted for the 1-for-25 reverse split by Nov 6, 2024: each earlier count is divided by the ratio of every split after it.
From the share count on the cover of each 10-Q and 10-K, dated as each cover states.
Follow ALGS
New shelves, offerings, 10-Qs and 10-Ks from ALGS, explained in plain English when they reach EDGAR.
Watch ALGS in the app